Neoadjuvant Chemoradiotherapy for Esophageal Cancer: Is It Worthwhile?

BACKGROUND With promising results from several institutions, many centers began treating patients with esophageal cancer with neoadjuvant chemoradiotherapy (NC) followed by esophagectomy. This approach is demanding for the patient and has not been proved to be better than esophagectomy alone. OBJECT...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Archives of surgery (Chicago, IL. 1960) IL. 1960), 1998-07, Vol.133 (7), p.722-726
Hauptverfasser: Tamim, Wael Z, Davidson, Robert S, Quinlan, Robert M, O'Shea, Michael A, Orr, Richard K, Swanson, Richard S
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 726
container_issue 7
container_start_page 722
container_title Archives of surgery (Chicago, IL. 1960)
container_volume 133
creator Tamim, Wael Z
Davidson, Robert S
Quinlan, Robert M
O'Shea, Michael A
Orr, Richard K
Swanson, Richard S
description BACKGROUND With promising results from several institutions, many centers began treating patients with esophageal cancer with neoadjuvant chemoradiotherapy (NC) followed by esophagectomy. This approach is demanding for the patient and has not been proved to be better than esophagectomy alone. OBJECTIVE To assess survival time and measures of quality of life associated with NC. DESIGN A retrospective review during 1990 to 1996. SETTING The 3 tertiary academic hospitals affiliated with the University of Massachusetts Medical School, Worcester. PARTICIPANTS All patients (N=51) with cancer of the middle or lower esophagus who were treated with NC followed by esophagectomy during this period. MAIN OUTCOME MEASURES Median and 1-, 2-, and 3-year survival times; median preoperative treatment time (first office visit for surgical consultation before beginning NC to the date of surgery), median hospital stay, and postoperative swallowing function. RESULTS The median survival time of all patients was 16.3 months; 1-, 2-, and 3-year overall survival rates were 67%, 46%, and 39%, respectively. The median hospital stay was 12 days. The median postoperative treatment time was 3.3 months, which was 20% of the median survival time. Of the 51 patients, 19 were alive with a median follow-up time of 2.5 years. Twenty-nine percent of the patients had a complete pathological response with median and 1-, 2-, and 3-year survival rates of 17.5 months, 73%, 57%, and 57%, respectively. Palliation of dysphagia was excellent, with 44 (93%) of 47 operative survivors taking either a soft diet (18 [38]) or a regular(26 [55]) diet by the first postoperative visit. CONCLUSIONS Median survival time with NC followed by esophagectomy for resectable cancer of the esophagus does not appear to be significantly better than that reported for esophagectomy alone. Further, treatment time with NC consumed 20% of survival time. Examining only these outcome variables suggests that NC is not worthwhile. However, examining a longer-term outcome survival variable, such as 3-year survival time, suggests that NC followed by esophagectomy may result in greater long-term survival than that reported for esophagectomy alone. We conclude that further randomized, controlled studies are necessary before NC followed by esophagectomy is considered superior to esophagectomy alone for the treatment of resectable esophageal cancer.-->
doi_str_mv 10.1001/archsurg.133.7.722
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_80040679</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><ama_id>211653</ama_id><sourcerecordid>80040679</sourcerecordid><originalsourceid>FETCH-LOGICAL-a323t-e07903d17bb31361b8b9bbd343650b12ac068c73f717b40c878d48a14c681ac03</originalsourceid><addsrcrecordid>eNpdkF1r2zAUhsVY6dKuP2CDgSlld84kHVsfuxklpGsgtDctvRTHslw72FEm2Rv991VJ1kKvjuB9zoceQr4yOmeUsh8YbBun8DhnAHM5l5x_IDNWgspBFMVHMqOUFnki6SdyEuMmvbjS_Jgca6Gk1npGrm6cx3oz_cXtmC1aN_iAdefH1gXcPWWND9ky-l2Ljw77bIFb68LPbBWz1Zg9-DC2_9qud78-k6MG--jODvWU3F8t7xbX-fr292pxuc4ROIy5o1JTqJmsKmAgWKUqXVU1FCBKWjGOlgplJTQyIQW1Sqq6UMgKKxRLIZyS7_u5u-D_TC6OZuiidX2PW-enaFT6MBVSJ_D8HbjxU9im2wwHXpaalSxBfA_Z4GMMrjG70A0Yngyj5sWw-W_YJMNGmmQ4NX07TJ6qwdWvLQelKb845Bgt9k1Izrr4iqXtQktI2Jc9hgO-hYyJEuAZvB-MRw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>232559151</pqid></control><display><type>article</type><title>Neoadjuvant Chemoradiotherapy for Esophageal Cancer: Is It Worthwhile?</title><source>MEDLINE</source><source>American Medical Association Journals</source><source>Alma/SFX Local Collection</source><creator>Tamim, Wael Z ; Davidson, Robert S ; Quinlan, Robert M ; O'Shea, Michael A ; Orr, Richard K ; Swanson, Richard S</creator><creatorcontrib>Tamim, Wael Z ; Davidson, Robert S ; Quinlan, Robert M ; O'Shea, Michael A ; Orr, Richard K ; Swanson, Richard S</creatorcontrib><description>BACKGROUND With promising results from several institutions, many centers began treating patients with esophageal cancer with neoadjuvant chemoradiotherapy (NC) followed by esophagectomy. This approach is demanding for the patient and has not been proved to be better than esophagectomy alone. OBJECTIVE To assess survival time and measures of quality of life associated with NC. DESIGN A retrospective review during 1990 to 1996. SETTING The 3 tertiary academic hospitals affiliated with the University of Massachusetts Medical School, Worcester. PARTICIPANTS All patients (N=51) with cancer of the middle or lower esophagus who were treated with NC followed by esophagectomy during this period. MAIN OUTCOME MEASURES Median and 1-, 2-, and 3-year survival times; median preoperative treatment time (first office visit for surgical consultation before beginning NC to the date of surgery), median hospital stay, and postoperative swallowing function. RESULTS The median survival time of all patients was 16.3 months; 1-, 2-, and 3-year overall survival rates were 67%, 46%, and 39%, respectively. The median hospital stay was 12 days. The median postoperative treatment time was 3.3 months, which was 20% of the median survival time. Of the 51 patients, 19 were alive with a median follow-up time of 2.5 years. Twenty-nine percent of the patients had a complete pathological response with median and 1-, 2-, and 3-year survival rates of 17.5 months, 73%, 57%, and 57%, respectively. Palliation of dysphagia was excellent, with 44 (93%) of 47 operative survivors taking either a soft diet (18 [38]) or a regular(26 [55]) diet by the first postoperative visit. CONCLUSIONS Median survival time with NC followed by esophagectomy for resectable cancer of the esophagus does not appear to be significantly better than that reported for esophagectomy alone. Further, treatment time with NC consumed 20% of survival time. Examining only these outcome variables suggests that NC is not worthwhile. However, examining a longer-term outcome survival variable, such as 3-year survival time, suggests that NC followed by esophagectomy may result in greater long-term survival than that reported for esophagectomy alone. We conclude that further randomized, controlled studies are necessary before NC followed by esophagectomy is considered superior to esophagectomy alone for the treatment of resectable esophageal cancer.--&gt;</description><identifier>ISSN: 0004-0010</identifier><identifier>ISSN: 2168-6254</identifier><identifier>EISSN: 1538-3644</identifier><identifier>EISSN: 2168-6262</identifier><identifier>DOI: 10.1001/archsurg.133.7.722</identifier><identifier>PMID: 9687999</identifier><identifier>CODEN: ARSUAX</identifier><language>eng</language><publisher>Chicago, IL: American Medical Association</publisher><subject>Adenocarcinoma - mortality ; Adenocarcinoma - therapy ; Biological and medical sciences ; Carcinoma, Squamous Cell - mortality ; Carcinoma, Squamous Cell - therapy ; Chemotherapy, Adjuvant ; Esophageal Neoplasms - mortality ; Esophageal Neoplasms - therapy ; Esophagectomy ; Esophagus ; Follow-Up Studies ; Gastroenterology. Liver. Pancreas. Abdomen ; Humans ; Medical sciences ; Middle Aged ; Quality of Life ; Radiotherapy, Adjuvant ; Retrospective Studies ; Survival Rate ; Tumors</subject><ispartof>Archives of surgery (Chicago, IL. 1960), 1998-07, Vol.133 (7), p.722-726</ispartof><rights>1998 INIST-CNRS</rights><rights>Copyright American Medical Association Jul 1998</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://jamanetwork.com/journals/jamasurgery/articlepdf/10.1001/archsurg.133.7.722$$EPDF$$P50$$Gama$$H</linktopdf><linktohtml>$$Uhttps://jamanetwork.com/journals/jamasurgery/fullarticle/10.1001/archsurg.133.7.722$$EHTML$$P50$$Gama$$H</linktohtml><link.rule.ids>64,309,310,314,780,784,789,790,3340,23930,23931,25140,27924,27925,76489,76492</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=2326973$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9687999$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tamim, Wael Z</creatorcontrib><creatorcontrib>Davidson, Robert S</creatorcontrib><creatorcontrib>Quinlan, Robert M</creatorcontrib><creatorcontrib>O'Shea, Michael A</creatorcontrib><creatorcontrib>Orr, Richard K</creatorcontrib><creatorcontrib>Swanson, Richard S</creatorcontrib><title>Neoadjuvant Chemoradiotherapy for Esophageal Cancer: Is It Worthwhile?</title><title>Archives of surgery (Chicago, IL. 1960)</title><addtitle>Arch Surg</addtitle><description>BACKGROUND With promising results from several institutions, many centers began treating patients with esophageal cancer with neoadjuvant chemoradiotherapy (NC) followed by esophagectomy. This approach is demanding for the patient and has not been proved to be better than esophagectomy alone. OBJECTIVE To assess survival time and measures of quality of life associated with NC. DESIGN A retrospective review during 1990 to 1996. SETTING The 3 tertiary academic hospitals affiliated with the University of Massachusetts Medical School, Worcester. PARTICIPANTS All patients (N=51) with cancer of the middle or lower esophagus who were treated with NC followed by esophagectomy during this period. MAIN OUTCOME MEASURES Median and 1-, 2-, and 3-year survival times; median preoperative treatment time (first office visit for surgical consultation before beginning NC to the date of surgery), median hospital stay, and postoperative swallowing function. RESULTS The median survival time of all patients was 16.3 months; 1-, 2-, and 3-year overall survival rates were 67%, 46%, and 39%, respectively. The median hospital stay was 12 days. The median postoperative treatment time was 3.3 months, which was 20% of the median survival time. Of the 51 patients, 19 were alive with a median follow-up time of 2.5 years. Twenty-nine percent of the patients had a complete pathological response with median and 1-, 2-, and 3-year survival rates of 17.5 months, 73%, 57%, and 57%, respectively. Palliation of dysphagia was excellent, with 44 (93%) of 47 operative survivors taking either a soft diet (18 [38]) or a regular(26 [55]) diet by the first postoperative visit. CONCLUSIONS Median survival time with NC followed by esophagectomy for resectable cancer of the esophagus does not appear to be significantly better than that reported for esophagectomy alone. Further, treatment time with NC consumed 20% of survival time. Examining only these outcome variables suggests that NC is not worthwhile. However, examining a longer-term outcome survival variable, such as 3-year survival time, suggests that NC followed by esophagectomy may result in greater long-term survival than that reported for esophagectomy alone. We conclude that further randomized, controlled studies are necessary before NC followed by esophagectomy is considered superior to esophagectomy alone for the treatment of resectable esophageal cancer.--&gt;</description><subject>Adenocarcinoma - mortality</subject><subject>Adenocarcinoma - therapy</subject><subject>Biological and medical sciences</subject><subject>Carcinoma, Squamous Cell - mortality</subject><subject>Carcinoma, Squamous Cell - therapy</subject><subject>Chemotherapy, Adjuvant</subject><subject>Esophageal Neoplasms - mortality</subject><subject>Esophageal Neoplasms - therapy</subject><subject>Esophagectomy</subject><subject>Esophagus</subject><subject>Follow-Up Studies</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Quality of Life</subject><subject>Radiotherapy, Adjuvant</subject><subject>Retrospective Studies</subject><subject>Survival Rate</subject><subject>Tumors</subject><issn>0004-0010</issn><issn>2168-6254</issn><issn>1538-3644</issn><issn>2168-6262</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkF1r2zAUhsVY6dKuP2CDgSlld84kHVsfuxklpGsgtDctvRTHslw72FEm2Rv991VJ1kKvjuB9zoceQr4yOmeUsh8YbBun8DhnAHM5l5x_IDNWgspBFMVHMqOUFnki6SdyEuMmvbjS_Jgca6Gk1npGrm6cx3oz_cXtmC1aN_iAdefH1gXcPWWND9ky-l2Ljw77bIFb68LPbBWz1Zg9-DC2_9qud78-k6MG--jODvWU3F8t7xbX-fr292pxuc4ROIy5o1JTqJmsKmAgWKUqXVU1FCBKWjGOlgplJTQyIQW1Sqq6UMgKKxRLIZyS7_u5u-D_TC6OZuiidX2PW-enaFT6MBVSJ_D8HbjxU9im2wwHXpaalSxBfA_Z4GMMrjG70A0Yngyj5sWw-W_YJMNGmmQ4NX07TJ6qwdWvLQelKb845Bgt9k1Izrr4iqXtQktI2Jc9hgO-hYyJEuAZvB-MRw</recordid><startdate>19980701</startdate><enddate>19980701</enddate><creator>Tamim, Wael Z</creator><creator>Davidson, Robert S</creator><creator>Quinlan, Robert M</creator><creator>O'Shea, Michael A</creator><creator>Orr, Richard K</creator><creator>Swanson, Richard S</creator><general>American Medical Association</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>19980701</creationdate><title>Neoadjuvant Chemoradiotherapy for Esophageal Cancer: Is It Worthwhile?</title><author>Tamim, Wael Z ; Davidson, Robert S ; Quinlan, Robert M ; O'Shea, Michael A ; Orr, Richard K ; Swanson, Richard S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a323t-e07903d17bb31361b8b9bbd343650b12ac068c73f717b40c878d48a14c681ac03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Adenocarcinoma - mortality</topic><topic>Adenocarcinoma - therapy</topic><topic>Biological and medical sciences</topic><topic>Carcinoma, Squamous Cell - mortality</topic><topic>Carcinoma, Squamous Cell - therapy</topic><topic>Chemotherapy, Adjuvant</topic><topic>Esophageal Neoplasms - mortality</topic><topic>Esophageal Neoplasms - therapy</topic><topic>Esophagectomy</topic><topic>Esophagus</topic><topic>Follow-Up Studies</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Quality of Life</topic><topic>Radiotherapy, Adjuvant</topic><topic>Retrospective Studies</topic><topic>Survival Rate</topic><topic>Tumors</topic><toplevel>online_resources</toplevel><creatorcontrib>Tamim, Wael Z</creatorcontrib><creatorcontrib>Davidson, Robert S</creatorcontrib><creatorcontrib>Quinlan, Robert M</creatorcontrib><creatorcontrib>O'Shea, Michael A</creatorcontrib><creatorcontrib>Orr, Richard K</creatorcontrib><creatorcontrib>Swanson, Richard S</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Archives of surgery (Chicago, IL. 1960)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tamim, Wael Z</au><au>Davidson, Robert S</au><au>Quinlan, Robert M</au><au>O'Shea, Michael A</au><au>Orr, Richard K</au><au>Swanson, Richard S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Neoadjuvant Chemoradiotherapy for Esophageal Cancer: Is It Worthwhile?</atitle><jtitle>Archives of surgery (Chicago, IL. 1960)</jtitle><addtitle>Arch Surg</addtitle><date>1998-07-01</date><risdate>1998</risdate><volume>133</volume><issue>7</issue><spage>722</spage><epage>726</epage><pages>722-726</pages><issn>0004-0010</issn><issn>2168-6254</issn><eissn>1538-3644</eissn><eissn>2168-6262</eissn><coden>ARSUAX</coden><abstract>BACKGROUND With promising results from several institutions, many centers began treating patients with esophageal cancer with neoadjuvant chemoradiotherapy (NC) followed by esophagectomy. This approach is demanding for the patient and has not been proved to be better than esophagectomy alone. OBJECTIVE To assess survival time and measures of quality of life associated with NC. DESIGN A retrospective review during 1990 to 1996. SETTING The 3 tertiary academic hospitals affiliated with the University of Massachusetts Medical School, Worcester. PARTICIPANTS All patients (N=51) with cancer of the middle or lower esophagus who were treated with NC followed by esophagectomy during this period. MAIN OUTCOME MEASURES Median and 1-, 2-, and 3-year survival times; median preoperative treatment time (first office visit for surgical consultation before beginning NC to the date of surgery), median hospital stay, and postoperative swallowing function. RESULTS The median survival time of all patients was 16.3 months; 1-, 2-, and 3-year overall survival rates were 67%, 46%, and 39%, respectively. The median hospital stay was 12 days. The median postoperative treatment time was 3.3 months, which was 20% of the median survival time. Of the 51 patients, 19 were alive with a median follow-up time of 2.5 years. Twenty-nine percent of the patients had a complete pathological response with median and 1-, 2-, and 3-year survival rates of 17.5 months, 73%, 57%, and 57%, respectively. Palliation of dysphagia was excellent, with 44 (93%) of 47 operative survivors taking either a soft diet (18 [38]) or a regular(26 [55]) diet by the first postoperative visit. CONCLUSIONS Median survival time with NC followed by esophagectomy for resectable cancer of the esophagus does not appear to be significantly better than that reported for esophagectomy alone. Further, treatment time with NC consumed 20% of survival time. Examining only these outcome variables suggests that NC is not worthwhile. However, examining a longer-term outcome survival variable, such as 3-year survival time, suggests that NC followed by esophagectomy may result in greater long-term survival than that reported for esophagectomy alone. We conclude that further randomized, controlled studies are necessary before NC followed by esophagectomy is considered superior to esophagectomy alone for the treatment of resectable esophageal cancer.--&gt;</abstract><cop>Chicago, IL</cop><pub>American Medical Association</pub><pmid>9687999</pmid><doi>10.1001/archsurg.133.7.722</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0004-0010
ispartof Archives of surgery (Chicago, IL. 1960), 1998-07, Vol.133 (7), p.722-726
issn 0004-0010
2168-6254
1538-3644
2168-6262
language eng
recordid cdi_proquest_miscellaneous_80040679
source MEDLINE; American Medical Association Journals; Alma/SFX Local Collection
subjects Adenocarcinoma - mortality
Adenocarcinoma - therapy
Biological and medical sciences
Carcinoma, Squamous Cell - mortality
Carcinoma, Squamous Cell - therapy
Chemotherapy, Adjuvant
Esophageal Neoplasms - mortality
Esophageal Neoplasms - therapy
Esophagectomy
Esophagus
Follow-Up Studies
Gastroenterology. Liver. Pancreas. Abdomen
Humans
Medical sciences
Middle Aged
Quality of Life
Radiotherapy, Adjuvant
Retrospective Studies
Survival Rate
Tumors
title Neoadjuvant Chemoradiotherapy for Esophageal Cancer: Is It Worthwhile?
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T19%3A05%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Neoadjuvant%20Chemoradiotherapy%20for%20Esophageal%20Cancer:%20Is%20It%20Worthwhile?&rft.jtitle=Archives%20of%20surgery%20(Chicago,%20IL.%201960)&rft.au=Tamim,%20Wael%20Z&rft.date=1998-07-01&rft.volume=133&rft.issue=7&rft.spage=722&rft.epage=726&rft.pages=722-726&rft.issn=0004-0010&rft.eissn=1538-3644&rft.coden=ARSUAX&rft_id=info:doi/10.1001/archsurg.133.7.722&rft_dat=%3Cproquest_cross%3E80040679%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=232559151&rft_id=info:pmid/9687999&rft_ama_id=211653&rfr_iscdi=true